Literature DB >> 11333897

Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV.

M S Parcells1, S F Lin, R L Dienglewicz, V Majerciak, D R Robinson, H C Chen, Z Wu, G R Dubyak, P Brunovskis, H D Hunt, L F Lee, H J Kung.   

Abstract

Chemokines induce chemotaxis, cell migration, and inflammatory responses. We report the identification of an interleukin-8 (IL-8) homolog, termed vIL-8, encoded within the genome of Marek's disease virus (MDV). The 134-amino-acid vIL-8 shares closest homology to mammalian and avian IL-8, molecules representing the prototype CXC chemokine. The gene for vIL-8 consists of three exons which map to the BamHI-L fragment within the repeats flanking the unique long region of the MDV genome. A 0.7-kb transcript encoding vIL-8 was detected in an n-butyrate-treated, MDV-transformed T-lymphoblastoid cell line, MSB-1. This induction is essentially abolished by cycloheximide and herpesvirus DNA polymerase inhibitor phosphonoacetate, indicating that vIL-8 is expressed with true late (gamma2) kinetics. Baculovirus-expressed vIL-8 was found to be secreted into the medium and shown to be functional as a chemoattractant for chicken peripheral blood mononuclear cells but not for heterophils. To characterize the function of vIL-8 with respect to MDV infection in vivo, a recombinant MDV was constructed with a deletion of all three exons and a soluble-modified green fluorescent protein (smGFP) expression cassette inserted at the site of deletion. In two in vivo experiments, the vIL-8 deletion mutant (RB1BvIL-8DeltasmGFP) showed a decreased level of lytic infection in comparison to its parent virus, an equal-passage-level parent virus, and to another recombinant MDV containing the insertion of a GFP expression cassette at the nonessential US2 gene. RB1BvIL-8DeltasmGFP retained oncogenicity, albeit at a greatly reduced level. Nonetheless, we have been able to establish a lymphoblastoid cell line from an RB1BvIL-8DeltasmGFP-induced ovarian lymphoma (MDCC-UA20) and verify the presence of a latent MDV genome lacking vIL-8. Taken together, these data describe the identification and characterization of a chemokine homolog encoded within the MDV genome that is dispensable for transformation but may affect the level of MDV in vivo lytic infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333897      PMCID: PMC114921          DOI: 10.1128/JVI.75.11.5159-5173.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  Signal peptidases in prokaryotes and eukaryotes--a new protease family.

Authors:  R E Dalbey; G Von Heijne
Journal:  Trends Biochem Sci       Date:  1992-11       Impact factor: 13.807

2.  Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity.

Authors:  J M Schröder; U Mrowietz; E Morita; E Christophers
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

3.  Characterization of reticuloendotheliosis virus-transformed avian T-lymphoblastoid cell lines infected with Marek's disease virus.

Authors:  W D Pratt; R W Morgan; K A Schat
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 4.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

5.  Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes.

Authors:  A Walz; P Peveri; H Aschauer; M Baggiolini
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

6.  Transfection of chicken embryo fibroblasts with Marek's disease virus DNA.

Authors:  R W Morgan; J L Cantello; C H McDermott
Journal:  Avian Dis       Date:  1990 Apr-Jun       Impact factor: 1.577

7.  Induction of interleukin-8 gene expression is associated with herpes simplex virus infection of human corneal keratocytes but not human corneal epithelial cells.

Authors:  J E Oakes; C A Monteiro; C L Cubitt; R N Lausch
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Complete sequence of the chicken glyceraldehyde-3-phosphate dehydrogenase gene.

Authors:  E M Stone; K N Rothblum; M C Alevy; T M Kuo; R J Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Isolation and characterization of Marek's disease virus (MDV) cDNAs mapping to the BamHI-I2, BamHI-Q2, and BamHI-L fragments of the MDV genome from lymphoblastoid cells transformed and persistently infected with MDV.

Authors:  Q Peng; M Zeng; Z A Bhuiyan; E Ubukata; A Tanaka; M Nonoyama; Y Shirazi
Journal:  Virology       Date:  1995-11-10       Impact factor: 3.616

10.  A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes.

Authors:  D Bruch-Gerharz; K Fehsel; C Suschek; G Michel; T Ruzicka; V Kolb-Bachofen
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  51 in total

1.  Differential cytokine responses following Marek's disease virus infection of chickens differing in resistance to Marek's disease.

Authors:  Pete Kaiser; Greg Underwood; Fred Davison
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.

Authors:  Timo Schippers; Keith Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication.

Authors:  Blanca Lupiani; Lucy F Lee; Xiaoping Cui; Isabel Gimeno; Amy Anderson; Robin W Morgan; Robert F Silva; Richard L Witter; Hsing-Jien Kung; Sanjay M Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

4.  Characterization of a very virulent Marek's disease virus mutant expressing the pp38 protein from the serotype 1 vaccine strain CVI988/Rispens.

Authors:  Lucy F Lee; Xiaoping Cui; Zhizhong Cui; Isabel Gimeno; Blanca Lupiani; Sanjay M Reddy
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

5.  Nuclear localization and dynamic properties of the Marek's disease virus oncogene products Meq and Meq/vIL8.

Authors:  Jonathan M Anobile; Vaithilingaraja Arumugaswami; Danielle Downs; Kirk Czymmek; Mark Parcells; Carl J Schmidt
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 6.  Alphaherpesviruses and chemokines: pas de deux not yet brought to perfection.

Authors:  Gerlinde R Van de Walle; Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  Clustering of mutations within the inverted repeat regions of a serially passaged attenuated gallid herpesvirus type 2 strain.

Authors:  Stephen J Spatz; Cary Rue; Daniel Schumacher; Nikolaus Osterrieder
Journal:  Virus Genes       Date:  2008-05-31       Impact factor: 2.332

8.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

9.  Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency.

Authors:  Xiaoping Cui; Lucy F Lee; Willie M Reed; Hsing-Jien Kung; Sanjay M Reddy
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Molecular and pathogenicity characterization of Gallid herpesvirus 2 newly isolated in China from 2009 to 2013.

Authors:  Yan-Ping Zhang; Hong-Chao Lv; Ke-Yan Bao; Yu-Long Gao; Hong-Lei Gao; Xiao- le Qi; Hong-Yu Cui; Yong-Qiang Wang; Kai Li; Li Gao; Xiao-Mei Wang; Chang-Jun Liu
Journal:  Virus Genes       Date:  2015-11-26       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.